Regenerative Potential of Spermatogenesis after Gonadotoxic Therapies - Male Germline Stem Cells Developmental and Regenerative Potential - page 197

in rodents is not yet known. Knowledge of the mechanism should allow the
identification of treatment targets downstream from the initial action of the hor-
mones. It may be possible to modulate those targets to release the blockade in
spermatogenic differentiation, while maintaining hormone levels, which should
allow spermatogonial differentiation in primates. This approach may be useful to
enhance the recovery of spermatogenesis and sperm count in toxicant-exposed
human males.
Acknowledgments The authors' research included in this chapter was supported by National
Institutes of Health grant ES-08075 from the National Institute of Environmental Health Sciences.
We thank Walter Pagel for very helpful editorial assistance.
References
Allard EK & Boekelheide K 1996 Fate of germ cells in 2,5-hexanedione-induced testicular injury.
II. Atrophy persists due to a reduced stem cell mass and ongoing apoptosis. Toxicol. Appl.
Pharmacol. 137 149-156.
Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F & Bacigalupo A 2002 Semen analy-
sis following allogeneic bone marrow transplantation. Additional data for evidence-based
counselling. Bone Marrow Transplant . 30 447-451.
Blanchard KT, Lee J & Boekelheide K 1998 Leuprolide, a gonadotropin-releasing hormone ago-
nist, reestablishes spermatogenesis after 2,5-hexanedione-induced irreversible testicular injury
in the rat, resulting in normalized stem cell factor expression. Endocrinology 139 236-244.
Boekelheide K & Hall SJ 1991 2,5-Hexanedione exposure in the rat results in long-term testicular
atrophy despite the presence of residual spermatogonia. J. Androl. 12 18-26.
Boekelheide K, Schoenfeld HA, Hall SJ, Weng CC, Shetty G, Leith J, Harper J, Sigman M, Hess
DL & Meistrich ML 2005 Gonadotropin-releasing hormone antagonist (Cetrorelix) therapy
fails to protect nonhuman primates ( Macaca arctoides ) from radiation-induced spermatogenic
failure. J. Androl. 26 222-234.
Brennemann W, Brensing KA, Leipner N, Boldt I & Klingmuller D 1994 Attempted protection of
spermatogenesis from irradiation in patients with seminoma by D-tryptophan-6 luteinizing
hormone releasing hormone. Clin. Investig. 72 838-842.
Brinster RL & Zimmermann JW 1994 Spermatogenesis following male germ-cell transplantation.
Proc. Natl Acad. Sci. USA 91 11298-11302.
Bucci LR & Meistrich ML 1987 Effects of busulfan on murine spermatogenesis: cytotoxicity,
sterility, sperm abnormalities, and dominant lethal mutations. Mutat. Res. 176 259-268.
Bucci LR, Brock WA & Meistrich ML 1985 Heterogeneity of high-mobility-group protein 2.
Enrichment of a rapidly migrating form in testis. Biochem. J. 229 233-240.
Chan PT, Palermo GD, Veeck LL, Rosenwaks Z & Schlegel PN 2001 Testicular sperm extraction
combined with intracytoplasmic sperm injection in the treatment of men with persistent azoo-
spermia postchemotherapy. Cancer 92 1632-1637.
Clark ST, Radford JA, Crowther D, Swindell R & Shalet SM 1995 Gonadal function following
chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid
regimen. J. Clin. Oncol. 13 134-139.
Clermont Y 1966 Renewal of spermatogonia in man. Am. J. Anat. 118 509-524.
Clermont Y 1969 Two classes of spermatogonial stem cells in the monkey ( Cercopithecus aethi-
ops ). Am. J. Anat. 126 57-71.
Clermont Y & Antar M 1973 Duration of the cycle of the seminiferous epithelium and the sper-
matogonial renewal in the monkey Macaca arctoides . Am. J. Anat. 136 153-165.